Cargando…
Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis
Breast cancer is a heterogeneous disease that can be subdivided into clinical, histopathological and molecular subtypes (luminal A-like, luminal B-like/HER2-negative, luminal B-like/HER2-positive, HER2-positive, and triple-negative). The study of new molecular factors is essential to obtain further...
Autores principales: | Perez-Janices, Noemi, Blanco-Luquin, Idoia, Torrea, Natalia, Liechtenstein, Therese, Escors, David, Cordoba, Alicia, Vicente-Garcia, Francisco, Jauregui, Isabel, De La Cruz, Susana, Illarramendi, José Juan, Coca, Valle, Berdasco, Maria, Kochan, Grazyna, Ibañez, Berta, Lera, José Miguel, Guerrero-Setas, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695163/ https://www.ncbi.nlm.nih.gov/pubmed/26284587 |
Ejemplares similares
-
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
por: Escors, David, et al.
Publicado: (2013) -
CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
por: Martín-Sánchez, Esperanza, et al.
Publicado: (2017) -
A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice
por: Liechtenstein, Therese, et al.
Publicado: (2014) -
Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications
por: Liechtenstein, Therese, et al.
Publicado: (2013) -
EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas
por: Perez-Janices, Noemi, et al.
Publicado: (2015)